Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes

Diabetes

Volumn 58, Issue 6, 2009, Pages 1382-1390

  Silva, Kamila C ^a   Rosales, Mariana A B ^a   Biswas, Subrata K ^a   De Faria, Jose B Lopes ^a   De Faria, Jacqueline M Lopes ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; 8 HYDROXYDEOXYGUANOSINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; GLUTATHIONE; LISINOPRIL; PROTEIN BCL 2; UNCOUPLING PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN MITOCHONDRION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; HYPERTENSION; MITOCHONDRIAL MEMBRANE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RETINA DEGENERATION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DNA DAMAGE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LOSARTAN; MITOCHONDRIA; OXIDATIVE STRESS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, ANGIOTENSIN;

EID: 66649114798     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-0166     Document Type: Article

References (50)

1. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713 (Pubitemid 28414300)
2. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-1815
3. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28-31
4. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study Group: Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008;372:1394-1402
5. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group: Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008;372:1385-1393
6. Danser AH, van den Dorpel MA, Deinum J, Derkx FH, Franken AA, Peperkamp E, de Jong PT, Schalekamp MA. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989;68:160-167 (Pubitemid 19028740)
7. Nagai N, Izumi-Nagai K, Oike Y, Koto T, Satofuka S, Ozawa Y, Yamashiro K, Inoue M, Tsubota K, Umezawa K, Ishida S. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci 2007;48:4342-4350
8. Funatsu H, Yamashita H, Nakanishi Y, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2002;86:311-315 (Pubitemid 34206346)
9. Kurihara T, Ozawa Y, Nagai N, Shinoda K, Noda K, Imamura Y, Tsubota K, Okano H, Oike Y, Ishida S. Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes 2008;57:2191-2198
10. Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001;50:1938-1942
11. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820 (Pubitemid 34000785)
12. Kowluru RA, Abbas SN. Diabetes-induced mitochondrial dysfunction in the retina. Invest Ophthalmol Vis Sci 2003;44:5327-5334 (Pubitemid 37475406)
13. Boveris A. Mitochondrial production of superoxide radical and hydrogen peroxide. Adv Exp Med Biol 1977;78:67-82
14. Pinto CC, Silva KC, Biswas SK, Martins N, Lopes de Faria JB, Lopes de Faria JM. Arterial hypertension exacerbates oxidative stress in early diabetic retinopathy. Free Radic Res 2007;41:1151-1158 (Pubitemid 47470853)
15. Giardino I, Fard AK, Hatchell DL, Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 1998;47:1114-1120 (Pubitemid 28294555)
16. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996;97:2883-2890 (Pubitemid 26197103)
17. Cogan DG, Toussaint D, Kuwabara T. Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol 1961;66:366-378
18. Engerman RL, Kern TS. Retinopathy in animal models of diabetes. Diabetes Metab Rev 1995;11:109-120
19. Bresnick GH, Korth K, Groo A, Palta M. Electroretinographic oscillatory potentials predict progression of diabetic retinopathy: preliminary report. Arch Ophthalmol 1984;102:1307-1311 (Pubitemid 14071831)
20. Lopes de Faria JM, Katsumi O, Cagliero E, Nathan D, Hirose T. Neurovisual abnormalities preceding the retinopathy in patients with long-term type 1 diabetes mellitus. Graefes Arch Clin Exp Ophthalmol 2001;239:643-648 (Pubitemid 32927012)
21. Carrasco E, Hernández C, Miralles A, Huguet P, Farrés J, Simó R. Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care 2007;30:2902-2908 (Pubitemid 350083143)
22. Carrasco E, Hernández C, de Torres I, Farrés J, Simó R. Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation. Mol Vis 2008;14:1496-1502
23. Li Y, Zhu H, Kuppusamy P, Roubaud V, Zweier JL, Trush MA. Validation of lucigenin (bis-N-methylacridinium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems. J Biol Chem 1998;273:2015-2023 (Pubitemid 28069247)
24. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976;72:248-254
25. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med 1963;61:882-888
26. Picaud S, Peichl L, Franceschini N. Dye-induced photolesion in the mammalian retina: glial and neuronal reactions. J Neurosci Res 1993;35: 629-642 (Pubitemid 23226715)
27. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by bcl-2: release of cytochrome c from mitochondria blocked. Science 1997;275:1129-1132 (Pubitemid 27097312)
28. Cui Y, Xu X, Bi H, Zhu Q, Wu J, Xia X, Qiushi Ren, Ho PC. Expression modification of uncoupling proteins and MnSOD in retinal endothelial cells and pericytes induced by high glucose: the role of reactive oxygen species in diabetic retinopathy. Exp Eye Res 2006;83:807-816 (Pubitemid 44308613)
29. Jung KH, Chu K, Lee ST, Kim SJ, Song EC, Kim EH, Park DK, Sinn DI, Kim JM, Kim M, Roh JK. Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther 2007;322:1051-1058 (Pubitemid 47295814)
30. Phipps JA, Wilkinson-Berka JL, Fletcher EL. Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol. Invest Ophthalmol Vis Sci 2007;48:927-934
31. Holopigian K, Greenstein VC, Seiple W, Hood DC, Carr RE. Evidence for photoreceptor changes in patients with diabetic retinopathy. Invest Ophthalmol Vis Sci 1997;38:2355-2365 (Pubitemid 27446953)
32. Phipps JA, Fletcher EL, Vingrys AJ. Paired-flash identification of rod and cone dysfunction in the diabetic rat. Invest Ophthalmol Vis Sci 2004;45: 4592-4600 (Pubitemid 39564688)
33. Yu BP. Cellular defenses against damage from reactive oxygen species. Physiol Rev 1994;74:139-162 (Pubitemid 24045676)
34. Kato S, Ishita S, Sugawara K, Mawatari K. Cysteine/glutamate antiporter expression in retinal Mü ller cells: implications for DL-aminoadipate toxicity. Neuroscience 1993;57:473-482 (Pubitemid 23345316)
35. Ewing JF, Maines MD. Glutathione depletion induces heme oxygenase-1 (HSP32) mRNA and protein in rat brain. J Neurochem 1993;60:1512-1519 (Pubitemid 23986322)
36. Stocker R, Peterhans E. Antioxidant properties of conjugated bilirubin and biliverdin: biologically relevant scavenging of hypochlorous acid. Free Rad Res Commun 1989;6:57-66 (Pubitemid 19109795)
37. Vincent SH. Oxidative effects of heme and porphyrins on proteins and lipids. Semin Hematol 1989;26:105-113 (Pubitemid 19128329)
38. Kurihara T, Ozawa Y, Shinoda K, Nagai N, Inoue M, Oike Y, Tsubota K, Ishida S, Okano H. Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. Invest Ophthalmol Vis Sci 2006;47:5545-5552 (Pubitemid 46723808)
39. Sugiyama T, Okuno T, Fukuhara M, Oku H, Ikeda T, Obayashi H, Ohta M, Fukui M, Hasegawa G, Nakamura N. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes. Exp Eye Res 2007;85: 406-412 (Pubitemid 47259058)
40. Wilkinson-Berka JL, Tan G, Jaworski K, Ninkovic S. Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina. Am J Hypertens 2007;20:423-430 (Pubitemid 46441750)
41. Matsubara H. Pathological role of angiotensin II type 2 receptor in cardiovascular and renal disease. Circulation 1998;83:1182-1191 (Pubitemid 29006033)
42. Imanishi T, Kobayashi K, Kuroi A, Mochizuki S, Goto M, Yoshida K, Akasaka T. Effects of angiotensin II on NO bioavailability evaluated using a catheter-type NO sensor. Hypertension 2006;48:1058-1065 (Pubitemid 44772708)
43. Lee CI, Liu X, Zweier JL. Regulation of xanthine oxidase by nitric oxide and peroxynitrite. J Biol Chem 2000;275:9369-9376 (Pubitemid 30185161)
44. Nishikawa T, Kukidome D, Sonoda K, Fujisawa K, Matsuhisa T, Motoshima H, Matsumura T, Araki E. Impact of mitochondrial ROS production on diabetic vascular complications. Diabetes Res Clin Pract 2007;77:S41-S45 (Pubitemid 47212551)
45. Hoegger MJ, Lieven CJ, Levin LA. Differential production of superoxide by neuronal mitochondria. BMC Neurosci 2008;9:4
46. Sandbach JM, Coscun PE, Grossniklaus HE, Kokoszka JE, Newman NJ, Wallace DC. Ocular pathology in mitochondrial superoxide dismutase (Sod2)-deficient mice. Invest Ophthalmol Vis Sci 2001;42:2173-2178 (Pubitemid 32848843)
47. Kowluru RA, Atasi L, Ho YS. Role of mitochondrial superoxide dismutase in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 2006;47:1594-1599 (Pubitemid 46780770)
48. Takahashi A, Masuda A, Sun M, Centonze VE, Herman B. Oxidative stress-induced apoptosis is associated with alterations in mitochondrial caspase activity and Bcl-2-dependent alterations in mitochondrial pH (pHm). Brain Res Bull 2004;62:497-504 (Pubitemid 38253035)
49. Kimura S, Zhang GX, Nishiyama A, Shokoji T, Yao L, Fan YY, Rahman M, Abe Y. Mitochondria-derived reactive oxygen species and vascular MAP kinases: comparison of angiotensin II and diazoxide. Hypertension 2005; 45:438-444 (Pubitemid 40315815)
50. Zhang DX, Chen YF, Campbell WB, Zou AP, Gross GJ, Li PL. Characteristics and superoxide-induced activation of reconstituted myocardial mitochondrial ATP-sensitive potassium channels. Circ Res 2001;89:1177-1183 (Pubitemid 34627876)